Article Text

PDF
PP-053 Evaluation of 5 compounded formulations for the treatment of oral mucositis in cancer patients
  1. J Ramos Rodríguez1,
  2. F Gutiérrez Nicolás1,
  3. I González Perera1,
  4. GJ Nazco Casariego1,
  5. MM Viña Romero2,
  6. GA González de la Fuente1,
  7. G Calzado Gómez1,
  8. S García Gil1
  1. 1Hospital Universitario de Canarias, Pharmacy, Santa Cruz de Tenerife, Spain
  2. 2Hospital Universitario Nuestra Señora de la Candelaria, Pharmacy, Santa Cruz de Tenerife, Spain

Abstract

Background Oral mucositis (OM) is a frequent complication of chemotherapy which severely affects patient quality of life. Management is generally based on topical compounded formulations.

Purpose To analyse the use of our compounded formulation of Lidollanten 1% for the treatment of OM in a tertiary hospital, to describe this and four other formulations and to perform a comparative cost analysis without including professional fees.

Material and methods We performed a 1 year retrospective study (January 2015–December 2015) involving all cancer patients who had used our compounded formulation during the study period. Patient data were obtained from the SAP application.

Results During the study period, we dispensed 3122 Lidollanten 1% preparations for 530 patients. The cost of preparation in the hospital was €1.55/100 mL, which meant €4 823.51/year. Different formulations for the treatment of OM are shown in the table.

View this table:

Conclusion According to our data, the least expensive formulation (from the point of view of acquisition cost) was No 2, which also happened to be that requiring the least processing time; it can be stored at room temperature, with an expiry time of 1 month. For these reasons, we believe it is the most efficient. Future studies will determine whether there are differences in effectiveness between the different formulations.

References and/or acknowledgements 1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer2014;120:1453–61.

No conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.